查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1929648

口腔崩解片市场按产品类型、技术、治疗领域、通路和最终用户划分，全球预测（2026-2032年）

Oral Disintegrating Strips Market by Product Type, Technology, Therapeutic Area, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，口腔崩坏片市场价值将达到 24.7 亿美元，到 2026 年将成长至 26.6 亿美元，到 2032 年将达到 39.2 亿美元，年复合成长率为 6.79%。

关键市场统计数据
基准年 2025 24.7亿美元
预计年份：2026年 26.6亿美元
预测年份 2032 39.2亿美元
复合年增长率 (%) 6.79%

口腔崩坏片简介：重点关注配方优势、以患者为中心的益处、不断发展的生产技术以及医疗保健领域的监管动态

口腔崩坏片是一种创新的给药形式，兼具便利性、病患依从性和製剂柔软性。这种薄膜与唾液接触后迅速溶解，无需用水即可给药，有助于提高吞嚥困难患者的用药依从性。这项技术在众多治疗领域中日益重要，尤其是在快速起效、剂量精准和患者体验至关重要的领域，例如随时随地缓解症状、儿童用药以及吞嚥障碍常见的老年护理。

製剂技术、病患行为、生产规模化和监管政策的变革性变化正在重塑口腔崩坏片的推广应用路径。

口腔崩坏片的最新发展趋势是技术进步和终端用户需求不断变化共同作用的结果。製剂科学已超越了基本的薄膜基质，涵盖了掩味策略、缓释技术以及使用共加工辅料来增强其在潮湿环境中的稳定性。这些技术进步降低了性能差异，并拓宽了治疗范围，促使那些先前认为此类剂型仅限于特定适应症的研发人员开始采用。

评估2025年美国关税对口溶锭供应链韧性、原料成本、配方调整方案和策略采购规划的影响

美国将于2025年生效的新关税将为依赖跨境供应链获取原材料、辅料和契约製造服务的相关人员带来新的营运挑战。关税调整将改变单位成本，并可能对利润率较低的产品线或依赖进口特种聚合物或活性药物成分的产品线产生特别显着的影响。从高关税地区采购成膜辅料或专有辅料的公司可能面临更高的投入成本，这将迫使它们重新评估供应商合约和库存策略。

我们透过細項分析来指导产品策略，整合了销售形式、最终用户人口统计、分销管道、配方技术和治疗领域差异化。

细分市场分析揭示了不同销售形式、最终用户、分销管道、技术和治疗领域所带来的独特机会和发展考量。基于销售形式，配方和包装设计必须满足非处方药 (OTC) 和处方药 (处方笺) 的监管要求和消费者期望。这些类别在标籤、给药说明和患者咨询方面需要不同的考虑。基于最终用户，目标族群的特征会影响口味掩蔽、剂量柔软性和易用性。成人、老年人和儿童群体各自具有独特的依从性驱动因素和临床优先事项，这些因素体现在剂量强度和包装规格上。

为在全球范围内成功推广口腔崩坏片，需要考虑区域策略因素以及监管、生产和商业方面的调整。

区域趋势影响着美洲、欧洲、中东和非洲以及亚太地区的监管、供应链设计和商业性执行重点。在美洲，完善的法规结构和成熟的医药基础设施促进了临床开发和经销伙伴的精简，同时以患者为中心的定位和直接面向消费者的销售管道也日益受到重视。在欧洲、中东和非洲，不同的监管环境和报销机制意味着市场进入策略必须更加细緻，通常需要根据各国的具体要求制定区域性稳定性策略和标籤策略。

在口腔崩坏片领域，塑造竞争地位的关键公司层面差异化因素包括配方平台、生产伙伴关係、品质系统和智慧财产权。

口腔崩坏片市场的竞争格局由那些在配方科学、生产能力和市场关係方面拥有优势的公司所主导。主要企业透过专有的辅料系统、掩味技术或平台化生产技术脱颖而出，从而实现高载药量、更高的稳定性和一致的溶出性能。合约研发生产机构 (CDMO) 在为寻求规模化生产或外包生产的客户提供技术转移支援和法规文件方面的专业知识方面发挥着至关重要的作用。

为製造商和开发商提供具体策略建议，以确保供应链的韧性、优化的配方、符合监管要求以及以患者为中心的商业化。

产业领导者应采取务实、以病人为中心的策略，在确保品质和供应连续性的同时，加速产品推广应用。首先，应使配方开发与明确的终端用户画像和通路保持一致，确保针对目标患者和管道优化口味掩蔽、片剂大小和包装。同时，应投资多家检验的关键辅料供应商，并考虑合格附近或区域合作伙伴，以降低关税波动和国际物流中断带来的风险。

严谨的调查方法为策略洞察提供支援：结合关键相关人员访谈、技术文献检验、供应商审核和情境分析。

我们的研究途径结合了与关键相关人员的对话、技术文献综合和定性检验，旨在全面了解口腔崩坏片的市场趋势。我们与製剂科学家、法规事务负责人、采购人员和销售主管进行了深入访谈，以收集关于研发挑战、供应链限制因素和市场推广驱动因素的跨职能观点。这些访谈让我们得以了解技术权衡、生产准备以及影响通路选择和标籤标註的实际因素。

对决定口腔崩坏片商业成功的技术进步、终端用户因素和操作要求进行全面分析

口腔崩坏片正处于一个转折点，技术成熟度、患者期望和商业性机会在此交汇，为产品差异化开闢了新的途径。製剂和生产技术的进步正在突破传统限制，使其能够更广泛地应用于不同的治疗领域和患者群体。同时，不断发展的分销模式和不断变化的人口结构趋势也提升了患者友好型、无需用水的剂型的价值，这些剂型有助于提高患者的用药依从性和满意度。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 按产品类型分類的口腔崩解片市场

  • 处方药
    • 品牌名称
    • 学名药
  • 非处方药
    • 品牌产品
    • 自有品牌
  • 营养保健品
    • 营养补充品
    • 草本产品

9. 按技术分類的口腔崩解片市场

  • 静电纺丝
  • 热熔挤出
  • 溶剂浇铸

第十章 按治疗领域分類的口腔崩解片市场

  • 过敏和感冒
    • 抗组织胺药物
    • 减充血剂
  • 循环系统
  • 中枢神经系统疾病
  • 消化器官系统
  • 疼痛管理
    • 止痛药
    • 非类固醇消炎剂（NSAIDs）
  • 维生素和营养补充剂
    • 综合维他命
    • 单一维生素

第十一章 按通路分類的口腔崩解片市场

  • 诊所和其他
  • 医院药房
  • 网路药房
  • 零售药房

第十二章 依最终使用者分類的口腔崩解片市场

  • 成人版
  • 老年人
  • 儿童

第十三章 口腔崩解片市场（依地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 口腔崩解片市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国口腔崩解片市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

16. 美国口腔崩解片市场

第十七章 中国口腔崩解片市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Aquestive Therapeutics, Inc.
  • BioDelivery Sciences International, Inc.
  • Corium International, Inc.
  • CURE Pharmaceutical Holding Corp.
  • GlaxoSmithKline plc
  • Indivior PLC
  • IntelGenx Technologies Corp.
  • Johnson & Johnson
  • LTS Lohmann Therapie-Systeme AG
  • Medherant Limited
  • Merck & Co., Inc.
  • MonoSol Rx LLC
  • NAL Pharma Co., Ltd.
  • Novartis International AG

第十八章 20. 其他值得关注的公司：

  • 辉瑞公司
  • 赛诺菲株式会社
  • 住友大日本製药株式会社
  • 太阳製药工业有限公司
  • Tesa LabTech
  • Viatris Inc.
  • ZIM Laboratories Limited
Product Code: MRR-0A380695186B

The Oral Disintegrating Strips Market was valued at USD 2.47 billion in 2025 and is projected to grow to USD 2.66 billion in 2026, with a CAGR of 6.79%, reaching USD 3.92 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.47 billion
Estimated Year [2026] USD 2.66 billion
Forecast Year [2032] USD 3.92 billion
CAGR (%) 6.79%

An introduction to oral disintegrating strips highlighting formulation benefits, patient-centric advantages, manufacturing evolution, and regulatory focus across healthcare settings

Oral disintegrating strips represent an innovative drug delivery format that blends convenience, patient adherence, and formulation flexibility. These thin films dissolve rapidly upon contact with saliva, enabling administrations without water and enhancing compliance among patient groups who experience swallowing difficulties. The technology is increasingly relevant across diverse therapeutic areas where rapid onset, dose accuracy, and patient experience matter, such as on-the-go symptomatic relief, pediatric dosing, or geriatric care settings where dysphagia is common.

Development pathways for these systems intersect formulation science, excipient selection, and manufacturing scalability. Advances in polymer chemistry and film-forming excipients have broadened the range of actives that can be stabilized and delivered effectively in strip form. Simultaneously, manufacturing innovations have reduced production variability and improved content uniformity, addressing earlier commercial hurdles. Regulatory expectations continue to evolve in parallel, placing emphasis on dissolution characteristics, stability under varied humidity conditions, and robust quality control practices to ensure consistent performance across batches.

Taken together, the format is positioned as a patient-centric alternative to traditional oral solid dosage forms, offering manufacturers and healthcare providers new avenues to differentiate products through improved adherence and user experience. As clinical stakeholders increasingly prioritize patient convenience and real-world usability, oral disintegrating strips are moving from niche application toward broader inclusion in product portfolios across therapeutic categories.

Transformative shifts in formulation, patient behavior, manufacturing scale-up, and regulatory clarity that are reshaping adoption pathways for oral disintegrating strips

Recent shifts in the oral disintegrating strips landscape reflect a convergence of technological refinement and evolving end-user expectations. Formulation science has advanced beyond basic film matrices to incorporate taste-masking strategies, controlled-release approaches, and co-processed excipients that enhance stability in humid environments. These technical improvements have reduced performance variability and enabled broader therapeutic application, supporting adoption by developers who previously regarded the format as limited to niche indications.

At the same time, changing healthcare delivery models and patient behaviors are reshaping demand patterns. Expansion of telehealth and direct-to-patient dispensing has elevated the importance of compact, easy-to-administer dosage forms. In parallel, demographic trends such as aging populations and increased prevalence of chronic conditions have intensified interest in formulations that address swallowing difficulties and polypharmacy challenges. Regulatory clarity around quality attributes and bioequivalence expectations has also matured, prompting more robust development programs and enabling clearer commercial pathways.

These shifts are transformative because they intersect across R&D, manufacturing, and commercialization. Developers are now able to leverage platform technologies for faster formulation iterations, manufacturers can scale production with improved process controls, and commercial teams have credible value propositions anchored in adherence and differentiated patient experience. The result is a landscape where oral disintegrating strips are increasingly considered a strategic option rather than a technical curiosity.

Assessment of 2025 United States tariff impacts on supply chain resilience, input costs, reformulation choices, and strategic procurement planning for oral disintegrating strips

The imposition of new tariffs within the United States in 2025 introduces an additional operational dimension for stakeholders that rely on cross-border supply chains for raw materials, excipients, or contract manufacturing services. Tariff adjustments alter unit economics and can disproportionately affect product lines with thin margins or those dependent on specialized imported polymers and active pharmaceutical ingredients. Companies that source film-forming excipients or proprietary additives from regions subject to higher duties may face increased input costs, necessitating reassessment of supplier contracts and inventory strategies.

In response, many firms are accelerating supplier diversification, qualifying alternative domestic or nearshore sources, and negotiating longer-term procurement agreements to stabilize pricing. Some developers and manufacturers are evaluating reformulation pathways that allow substitution of affected components without compromising efficacy or stability, while others are investing in backward integration to secure critical inputs. These strategic responses require close coordination among procurement, regulatory, and quality assurance teams to ensure changes meet performance and compliance requirements.

Additionally, tariff-driven cost pressures may influence commercialization sequencing and pricing strategies. Companies must weigh the trade-offs between maintaining list prices and absorbing incremental costs to protect market access. Ultimately, the tariff environment underscores the importance of resilient supply chains, proactive cost modeling, and flexible formulation strategies to mitigate disruption and sustain product continuity.

Integrated segmentation insights connecting sales type, end-user demographics, distribution channels, formulation technologies, and therapeutic area differentiation to guide product strategy

Segmentation analysis reveals differentiated opportunities and development considerations across sales types, end users, distribution channels, technologies, and therapeutic areas. Based on Sales Type, the formulation and packaging design must respond to the distinct regulatory requirements and consumer expectations associated with Over The Counter and Prescription categories, where labeling, dosing instructions, and patient counseling considerations differ. Based on End User, target population characteristics influence taste-masking, dose flexibility, and ease of handling, with Adult, Geriatric, and Pediatric cohorts each presenting unique adherence drivers and clinical priorities that inform dosage strength and strip size.

Based on Distribution Channel, route-to-patient logistics and presentation requirements vary across Clinics & Others, Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy, affecting packaging formats, unitization, and returns handling policies. Based on Technology, the choice among Electrospinning, Hot Melt Extrusion, and Solvent Casting determines the achievable drug load, film thickness, and production throughput, with each technique offering trade-offs between scalability and formulation complexity. Based on Therapeutic Area, product design must align with the clinical profile and administration context for categories such as Allergy & Cold, Cardiovascular, CNS Disorders, Gastrointestinal, Pain Management, and Vitamins & Nutritional Supplements, where the Allergy & Cold segment is further distinguished by Antihistamines and Decongestants, Pain Management by Analgesics and NSAIDs, and Vitamins & Nutritional Supplements by Multivitamins and Single Vitamins.

Integrating these segmentation lenses enables developers to prioritize technology investments and distribution strategies that align with the end-user needs and regulatory pathways for specific therapeutic targets, while also optimizing packaging and communication tactics to fit the chosen sales type and channel dynamics.

Regional strategic considerations and regulatory, manufacturing, and commercial adaptions required to successfully deploy oral disintegrating strips across global territories

Regional dynamics shape priorities for regulatory engagement, supply chain design, and commercial execution across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, regulatory frameworks and established pharmaceutical infrastructures favor streamlined clinical development and distribution partnerships, while patient-centric positioning and direct-to-consumer channels are increasingly influential. In Europe, Middle East & Africa, heterogeneous regulatory regimes and diverse reimbursement landscapes require nuanced go-to-market approaches and often necessitate localized stability and labeling strategies to meet varied national requirements.

In Asia-Pacific, rapid manufacturing scale-up, proximity to key raw material suppliers, and a large and diverse patient base create opportunities for both innovation and cost-competitive production models. Each region presents distinct considerations for intellectual property protection, regulatory dossier expectations, and post-market surveillance practices, which in turn affect timelines for product introduction and the selection of strategic partners. Cross-regional strategies that combine regional manufacturing hubs with local commercial partners can reduce logistical complexity and improve responsiveness to region-specific clinical needs.

A regional lens also influences decisions about clinical program design, comparator selection, and patient-reported outcome measures, all of which should be tailored to the regulatory expectations and healthcare utilization patterns of the target geography. Coordinated regional planning enhances the ability to scale manufacturing and distribution while maintaining compliance and maximizing adoption across diverse healthcare systems.

Key company-level differentiators in formulation platforms, manufacturing partnerships, quality systems, and intellectual property that shape competitive positioning in oral disintegrating strips

Competitive dynamics in the oral disintegrating strips space are shaped by companies that bring strength in formulation science, manufacturing capabilities, and route-to-market relationships. Leading developers differentiate through proprietary excipient systems, taste-masking technologies, or platform manufacturing know-how that enable higher drug loading, improved stability, and consistent dissolution performance. Contract development and manufacturing organizations play a pivotal role for clients seeking to outsource scale-up and production, offering technical transfer support and regulatory dossier preparation expertise.

Partnerships between innovator companies and specialist manufacturers are common, allowing brand owners to capitalize on third-party capabilities while preserving commercial focus. In addition, firms that invest in robust quality systems and humidity-controlled packaging solutions create competitive advantages by reducing product returns and ensuring longer shelf-life performance in diverse climates. Service providers that offer end-to-end support-from preformulation screening to commercial batch release-are particularly valuable for organizations that lack in-house film-formulation experience.

Intellectual property considerations and freedom-to-operate analyses are increasingly important as formulation platforms proliferate. Entities that protect core excipient combinations, manufacturing sequences, or coating techniques can create meaningful barriers to entry, particularly for higher-value therapeutic applications. For stakeholders evaluating partnerships or acquisitions, diligence should prioritize manufacturing reproducibility, regulatory track record, and the ability to adapt formulations for different distribution channels and end-user populations.

Actionable strategic recommendations for manufacturers and developers to ensure resilient supply chains, optimized formulations, regulatory alignment, and patient-centered commercialization

Industry leaders should adopt a pragmatic, patient-centered agenda that accelerates adoption while safeguarding quality and supply continuity. Begin by aligning formulation development with clearly defined end-user profiles and distribution routes so that taste-masking, strip sizing, and packaging are optimized for intended patients and channels. Simultaneously, invest in multiple validated suppliers for critical excipients and consider qualifying nearshore or regional partners to reduce exposure to tariff volatility and international logistics disruption.

Operationally, implement robust process controls and environmental monitoring for humidity-sensitive production steps, and prioritize packaging innovations that extend stability across diverse geographies. From a commercial perspective, build value propositions that emphasize adherence, ease of use, and clinical benefit, supported by real-world evidence or patient-reported outcomes where feasible. Engage early with regulatory authorities to clarify expectations for bioequivalence, dissolution parameters, and stability protocols to avoid downstream delays.

Finally, pursue targeted collaborations with contract manufacturers or clinical partners to accelerate time-to-market and de-risk scale-up. Use scenario planning to test the impact of input-cost variability, tariff shifts, and channel mix changes on pricing and profitability, and maintain a clear governance process for rapid decision-making when supply chain contingencies arise.

Rigorous research methodology combining primary stakeholder interviews, technical literature validation, supplier audits, and scenario analysis to underpin strategic insights

The research approach combines primary stakeholder engagement, technical literature synthesis, and qualitative validation to construct a robust view of the oral disintegrating strips landscape. Primary interviews were conducted with formulation scientists, regulatory affairs professionals, procurement leads, and commercial executives to capture cross-functional perspectives on development challenges, supply chain constraints, and adoption drivers. These conversations provided insight into technology trade-offs, manufacturing readiness, and the practical considerations that influence channel selection and labeling.

Technical literature and regulatory guidance documents were reviewed to validate dissolution targets, stability considerations, and bioavailability expectations for rapidly dissolving film formats. Supplier dialogues and manufacturing audits informed assessments of process capability, environmental control needs, and packaging requirements. Finally, scenario analysis and sensitivity testing were applied to evaluate the operational impact of input-cost changes, distribution shifts, and supplier disruptions, providing a practical foundation for the strategic recommendations offered.

This triangulated methodology ensures findings are grounded in both real-world operational experience and technical standards, offering decision-makers a balanced and actionable basis for R&D prioritization, supply chain design, and commercialization planning.

Concluding synthesis of technical progress, end-user drivers, and operational imperatives that determine successful commercialization of oral disintegrating strips

Oral disintegrating strips are at an inflection point where technical maturity, patient expectations, and commercial opportunity converge to create new pathways for product differentiation. Advances in formulation and manufacturing have addressed historical constraints, enabling broader applicability across therapeutic areas and patient populations. At the same time, evolving distribution models and demographic trends are increasing the value of patient-friendly, water-free administration formats that can improve adherence and patient satisfaction.

To capitalize on this momentum, stakeholders must integrate product design with pragmatic supply chain and regulatory strategies. Ensuring supplier diversity, investing in humidity-resilient packaging, and engaging regulators early are critical actions that reduce commercialization risk. Strategic collaborations and targeted investments in platform technologies can shorten development timelines and unlock higher-value therapeutic applications. Ultimately, success will favor organizations that combine technical excellence with operational resilience and clear, patient-centered commercial narratives.

By focusing on these coordinated priorities, developers and manufacturers can translate the promise of oral disintegrating strips into sustainable product portfolios that meet clinical needs and create durable competitive advantage.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Oral Disintegrating Strips Market, by Product Type

  • 8.1. Prescription
    • 8.1.1. Brand Name
    • 8.1.2. Generic
  • 8.2. Over-The-Counter
    • 8.2.1. Branded
    • 8.2.2. Private Label
  • 8.3. Nutraceutical
    • 8.3.1. Dietary Supplement
    • 8.3.2. Herbal Product

9. Oral Disintegrating Strips Market, by Technology

  • 9.1. Electrospinning
  • 9.2. Hot Melt Extrusion
  • 9.3. Solvent Casting

10. Oral Disintegrating Strips Market, by Therapeutic Area

  • 10.1. Allergy & Cold
    • 10.1.1. Antihistamines
    • 10.1.2. Decongestants
  • 10.2. Cardiovascular
  • 10.3. CNS Disorders
  • 10.4. Gastrointestinal
  • 10.5. Pain Management
    • 10.5.1. Analgesics
    • 10.5.2. NSAIDs
  • 10.6. Vitamins & Nutritional Supplements
    • 10.6.1. Multivitamins
    • 10.6.2. Single Vitamins

11. Oral Disintegrating Strips Market, by Distribution Channel

  • 11.1. Clinics & Others
  • 11.2. Hospital Pharmacy
  • 11.3. Online Pharmacy
  • 11.4. Retail Pharmacy

12. Oral Disintegrating Strips Market, by End User

  • 12.1. Adult
  • 12.2. Geriatric
  • 12.3. Pediatric

13. Oral Disintegrating Strips Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Oral Disintegrating Strips Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Oral Disintegrating Strips Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Oral Disintegrating Strips Market

17. China Oral Disintegrating Strips Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Aquestive Therapeutics, Inc.
  • 18.7. BioDelivery Sciences International, Inc.
  • 18.8. Corium International, Inc.
  • 18.9. CURE Pharmaceutical Holding Corp.
  • 18.10. GlaxoSmithKline plc
  • 18.11. Indivior PLC
  • 18.12. IntelGenx Technologies Corp.
  • 18.13. Johnson & Johnson
  • 18.14. LTS Lohmann Therapie-Systeme AG
  • 18.15. Medherant Limited
  • 18.16. Merck & Co., Inc.
  • 18.17. MonoSol Rx LLC
  • 18.18. NAL Pharma Co., Ltd.
  • 18.19. Novartis International AG

18.20. Other Noteworthy Players:

  • 18.21. Pfizer Inc.
  • 18.22. Sanofi S.A.
  • 18.23. Sumitomo Dainippon Pharma Co., Ltd.
  • 18.24. Sun Pharmaceutical Industries Ltd.
  • 18.25. Tesa Labtec GmbH
  • 18.26. Viatris Inc.
  • 18.27. ZIM Laboratories Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ORAL DISINTEGRATING STRIPS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ORAL DISINTEGRATING STRIPS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ORAL DISINTEGRATING STRIPS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRESCRIPTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRESCRIPTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRESCRIPTION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY BRAND NAME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY BRAND NAME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY BRAND NAME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY OVER-THE-COUNTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY OVER-THE-COUNTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY OVER-THE-COUNTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY OVER-THE-COUNTER, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRIVATE LABEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRIVATE LABEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRIVATE LABEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY NUTRACEUTICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY NUTRACEUTICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY NUTRACEUTICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY NUTRACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY DIETARY SUPPLEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY DIETARY SUPPLEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY DIETARY SUPPLEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY HERBAL PRODUCT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY HERBAL PRODUCT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY HERBAL PRODUCT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ELECTROSPINNING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ELECTROSPINNING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ELECTROSPINNING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY HOT MELT EXTRUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY HOT MELT EXTRUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY HOT MELT EXTRUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY SOLVENT CASTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY SOLVENT CASTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY SOLVENT CASTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ALLERGY & COLD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ALLERGY & COLD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ALLERGY & COLD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ALLERGY & COLD, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ANTIHISTAMINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ANTIHISTAMINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY DECONGESTANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY DECONGESTANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY DECONGESTANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY CNS DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY CNS DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY CNS DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY GASTROINTESTINAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY GASTROINTESTINAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ANALGESICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ANALGESICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ANALGESICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY NSAIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY NSAIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY NSAIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY VITAMINS & NUTRITIONAL SUPPLEMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY VITAMINS & NUTRITIONAL SUPPLEMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY VITAMINS & NUTRITIONAL SUPPLEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY VITAMINS & NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY MULTIVITAMINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY MULTIVITAMINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY MULTIVITAMINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY SINGLE VITAMINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY SINGLE VITAMINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY SINGLE VITAMINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY CLINICS & OTHERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY CLINICS & OTHERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY CLINICS & OTHERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS ORAL DISINTEGRATING STRIPS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRESCRIPTION, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS ORAL DISINTEGRATING STRIPS MARKET SIZE, BY OVER-THE-COUNTER, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS ORAL DISINTEGRATING STRIPS MARKET SIZE, BY NUTRACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS ORAL DISINTEGRATING STRIPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS ORAL DISINTEGRATING STRIPS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ALLERGY & COLD, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS ORAL DISINTEGRATING STRIPS MARKET SIZE, BY VITAMINS & NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS ORAL DISINTEGRATING STRIPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS ORAL DISINTEGRATING STRIPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRESCRIPTION, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY OVER-THE-COUNTER, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY NUTRACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ALLERGY & COLD, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY VITAMINS & NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRESCRIPTION, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY OVER-THE-COUNTER, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY NUTRACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ALLERGY & COLD, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY VITAMINS & NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRESCRIPTION, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY OVER-THE-COUNTER, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY NUTRACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ALLERGY & COLD, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY VITAMINS & NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE ORAL DISINTEGRATING STRIPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRESCRIPTION, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE ORAL DISINTEGRATING STRIPS MARKET SIZE, BY OVER-THE-COUNTER, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE ORAL DISINTEGRATING STRIPS MARKET SIZE, BY NUTRACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE ORAL DISINTEGRATING STRIPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE ORAL DISINTEGRATING STRIPS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ALLERGY & COLD, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE ORAL DISINTEGRATING STRIPS MARKET SIZE, BY VITAMINS & NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE ORAL DISINTEGRATING STRIPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE ORAL DISINTEGRATING STRIPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST ORAL DISINTEGRATING STRIPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRESCRIPTION, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST ORAL DISINTEGRATING STRIPS MARKET SIZE, BY OVER-THE-COUNTER, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST ORAL DISINTEGRATING STRIPS MARKET SIZE, BY NUTRACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST ORAL DISINTEGRATING STRIPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST ORAL DISINTEGRATING STRIPS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ALLERGY & COLD, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST ORAL DISINTEGRATING STRIPS MARKET SIZE, BY VITAMINS & NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST ORAL DISINTEGRATING STRIPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST ORAL DISINTEGRATING STRIPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRESCRIPTION, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY OVER-THE-COUNTER, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY NUTRACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ALLERGY & COLD, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY VITAMINS & NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC ORAL DISINTEGRATING STRIPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRESCRIPTION, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC ORAL DISINTEGRATING STRIPS MARKET SIZE, BY OVER-THE-COUNTER, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC ORAL DISINTEGRATING STRIPS MARKET SIZE, BY NUTRACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC ORAL DISINTEGRATING STRIPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC ORAL DISINTEGRATING STRIPS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ALLERGY & COLD, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC ORAL DISINTEGRATING STRIPS MARKET SIZE, BY VITAMINS & NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC ORAL DISINTEGRATING STRIPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC ORAL DISINTEGRATING STRIPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN ORAL DISINTEGRATING STRIPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRESCRIPTION, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN ORAL DISINTEGRATING STRIPS MARKET SIZE, BY OVER-THE-COUNTER, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN ORAL DISINTEGRATING STRIPS MARKET SIZE, BY NUTRACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN ORAL DISINTEGRATING STRIPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN ORAL DISINTEGRATING STRIPS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ALLERGY & COLD, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN ORAL DISINTEGRATING STRIPS MARKET SIZE, BY VITAMINS & NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN ORAL DISINTEGRATING STRIPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN ORAL DISINTEGRATING STRIPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. GCC ORAL DISINTEGRATING STRIPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. GCC ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. GCC ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRESCRIPTION, 2018-2032 (USD MILLION)
  • TABLE 219. GCC ORAL DISINTEGRATING STRIPS MARKET SIZE, BY OVER-THE-COUNTER, 2018-2032 (USD MILLION)
  • TABLE 220. GCC ORAL DISINTEGRATING STRIPS MARKET SIZE, BY NUTRACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 221. GCC ORAL DISINTEGRATING STRIPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 222. GCC ORAL DISINTEGRATING STRIPS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 223. GCC ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ALLERGY & COLD, 2018-2032 (USD MILLION)
  • TABLE 224. GCC ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 225. GCC ORAL DISINTEGRATING STRIPS MARKET SIZE, BY VITAMINS & NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 226. GCC ORAL DISINTEGRATING STRIPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 227. GCC ORAL DISINTEGRATING STRIPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION ORAL DISINTEGRATING STRIPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRESCRIPTION, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION ORAL DISINTEGRATING STRIPS MARKET SIZE, BY OVER-THE-COUNTER, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION ORAL DISINTEGRATING STRIPS MARKET SIZE, BY NUTRACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION ORAL DISINTEGRATING STRIPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION ORAL DISINTEGRATING STRIPS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ALLERGY & COLD, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION ORAL DISINTEGRATING STRIPS MARKET SIZE, BY VITAMINS & NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION ORAL DISINTEGRATING STRIPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION ORAL DISINTEGRATING STRIPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS ORAL DISINTEGRATING STRIPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRESCRIPTION, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS ORAL DISINTEGRATING STRIPS MARKET SIZE, BY OVER-THE-COUNTER, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS ORAL DISINTEGRATING STRIPS MARKET SIZE, BY NUTRACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS ORAL DISINTEGRATING STRIPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS ORAL DISINTEGRATING STRIPS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ALLERGY & COLD, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS ORAL DISINTEGRATING STRIPS MARKET SIZE, BY VITAMINS & NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS ORAL DISINTEGRATING STRIPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS ORAL DISINTEGRATING STRIPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. G7 ORAL DISINTEGRATING STRIPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 253. G7 ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. G7 ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRESCRIPTION, 2018-2032 (USD MILLION)
  • TABLE 255. G7 ORAL DISINTEGRATING STRIPS MARKET SIZE, BY OVER-THE-COUNTER, 2018-2032 (USD MILLION)
  • TABLE 256. G7 ORAL DISINTEGRATING STRIPS MARKET SIZE, BY NUTRACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 257. G7 ORAL DISINTEGRATING STRIPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 258. G7 ORAL DISINTEGRATING STRIPS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 259. G7 ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ALLERGY & COLD, 2018-2032 (USD MILLION)
  • TABLE 260. G7 ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 261. G7 ORAL DISINTEGRATING STRIPS MARKET SIZE, BY VITAMINS & NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 262. G7 ORAL DISINTEGRATING STRIPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 263. G7 ORAL DISINTEGRATING STRIPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 264. NATO ORAL DISINTEGRATING STRIPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. NATO ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. NATO ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRESCRIPTION, 2018-2032 (USD MILLION)
  • TABLE 267. NATO ORAL DISINTEGRATING STRIPS MARKET SIZE, BY OVER-THE-COUNTER, 2018-2032 (USD MILLION)
  • TABLE 268. NATO ORAL DISINTEGRATING STRIPS MARKET SIZE, BY NUTRACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 269. NATO ORAL DISINTEGRATING STRIPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 270. NATO ORAL DISINTEGRATING STRIPS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 271. NATO ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ALLERGY & COLD, 2018-2032 (USD MILLION)
  • TABLE 272. NATO ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 273. NATO ORAL DISINTEGRATING STRIPS MARKET SIZE, BY VITAMINS & NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 274. NATO ORAL DISINTEGRATING STRIPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 275. NATO ORAL DISINTEGRATING STRIPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 276. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES ORAL DISINTEGRATING STRIPS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRESCRIPTION, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES ORAL DISINTEGRATING STRIPS MARKET SIZE, BY OVER-THE-COUNTER, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED STATES ORAL DISINTEGRATING STRIPS MARKET SIZE, BY NUTRACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED STATES ORAL DISINTEGRATING STRIPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED STATES ORAL DISINTEGRATING STRIPS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED STATES ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ALLERGY & COLD, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED STATES ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED STATES ORAL DISINTEGRATING STRIPS MARKET SIZE, BY VITAMINS & NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED STATES ORAL DISINTEGRATING STRIPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED STATES ORAL DISINTEGRATING STRIPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA ORAL DISINTEGRATING STRIPS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 290. CHINA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. CHINA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRESCRIPTION, 2018-2032 (USD MILLION)
  • TABLE 292. CHINA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY OVER-THE-COUNTER, 2018-2032 (USD MILLION)
  • TABLE 293. CHINA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY NUTRACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 294. CHINA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 295. CHINA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 296. CHINA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ALLERGY & COLD, 2018-2032 (USD MILLION)
  • TABLE 297. CHINA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 298. CHINA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY VITAMINS & NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 299. CHINA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 300. CHINA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)